75 related articles for article (PubMed ID: 36494905)
1. Rh-endostatin plus camrelizumab and chemotherapy in first-line treatment of advanced non-small cell lung cancer: A multicenter retrospective study.
Pu X; Wang Q; Liu L; Chen B; Li K; Zhou Y; Sheng Z; Liu P; Tang Y; Xu L; Li J; Kong Y; Xu F; Xu Y; Wu L
Cancer Med; 2023 Apr; 12(7):7724-7733. PubMed ID: 36494905
[TBL] [Abstract][Full Text] [Related]
2. Camrelizumab plus famitinib in previously chemo-immunotherapy treated patients with advanced NSCLC: results from an open-label multicenter phase 2 basket study.
Ren S; Xiong A; Yu J; Wang X; Han B; Pan Y; Zhao J; Cheng Y; Hu S; Liu T; Li Y; Cheng Y; Feng J; Yi S; Gu S; Gao S; Luo Y; Liu Y; Liu C; Duan H; Wang S; Yang X; Fan J; Zhou C
Cancer Immunol Immunother; 2024 May; 73(7):124. PubMed ID: 38727837
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of camrelizumab combined with albumin-bound paclitaxel as third- or later-line regimen in patients with advanced non-small cell lung cancer.
Zhu J; Yu Y; Mei J; Chen S; Li J; Jiang S
Front Immunol; 2023; 14():1278573. PubMed ID: 38124737
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant Camrelizumab for Non-Small Cell Lung Cancer: A Retrospective Multicenter, Real-World Study (CTONG2004).
Liu SY; Chen Q; Zhou C; Zhang H; Li W; Chen J; Hu J; Wu L; Chen Q; Dai Q; Shan JZ; Xu F; Liu SM; Wu YL
Cancer Immunol Immunother; 2023 Jul; 72(7):2257-2265. PubMed ID: 36871274
[TBL] [Abstract][Full Text] [Related]
5. Low-dose anlotinib confers improved survival in combination with immune checkpoint inhibitor in advanced non-small cell lung cancer patients.
Yuan S; Peng L; Liu Y; Till BG; Yan X; Zhang J; Zhu L; Wang H; Zhang S; Li H; Gao Q; Wang Z
Cancer Immunol Immunother; 2023 Feb; 72(2):437-448. PubMed ID: 35931835
[TBL] [Abstract][Full Text] [Related]
6. Immune checkpoint inhibitors combined with angiogenic inhibitors in the treatment of locally advanced or metastatic lung adenocarcinoma patients.
Feng Y; Tang L; Wang H; Liu Y; Yang S; Lin L; Hu X; Shi Y
Cancer Immunol Immunother; 2023 Feb; 72(2):449-459. PubMed ID: 35934742
[TBL] [Abstract][Full Text] [Related]
7. Recombined humanized endostatin-induced suppression of HMGB1 expression inhibits proliferation of NSCLC cancer cells.
Meng FJ; Wang S; Yan YJ; Wang CY; Guan ZY; Zhang J
Thorac Cancer; 2019 Jan; 10(1):90-95. PubMed ID: 30485686
[TBL] [Abstract][Full Text] [Related]
8. Intrapleural Administration With Rh-Endostatin and Chemical Irritants in the Control of Malignant Pleural Effusion: A Systematic Review and Meta-Analysis.
Wang CQ; Huang XR; He M; Zheng XT; Jiang H; Chen Q; Fan TY; Zhan L; Ling J; Feng JH; Xiao X; Chen XF; Xiao Z
Front Oncol; 2021; 11():649999. PubMed ID: 34414103
[TBL] [Abstract][Full Text] [Related]
9. Is cryoablation still suitable for advanced non-small cell lung cancer after failure of first-line chemotherapy? A multicenter, prospective, randomized-controlled trial of eighty-seven patients.
Chen Y; Fang X; Wang D; Li Q; Zhang K; Li Y; Li J; Pang H; Cheng Z; Zhang C; Zhang C; Yang W; Zhu B; Fan H; Han C; An Y; Zhang L; Luo B; Zhang S; Lu T; Meng Y; Jiao Q; Tang H; Zhou T; Hu K
Cryobiology; 2024 Feb; 115():104864. PubMed ID: 38387752
[TBL] [Abstract][Full Text] [Related]
10. Camrelizumab induced immune related adverse event: Two case reports and literature review.
Ge L; Chen W; Zhang G; Wei F
Asian J Surg; 2024 Mar; ():. PubMed ID: 38522994
[No Abstract] [Full Text] [Related]
11. Immunotherapy combined with rh-endostatin improved clinical outcomes over immunotherapy plus chemotherapy for second-line treatment of advanced NSCLC.
Huang H; Zhong P; Zhu X; Fu S; Li S; Peng S; Liu Y; Lu Z; Chen L
Front Oncol; 2023; 13():1137224. PubMed ID: 37035161
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of immune checkpoint inhibitors combined with recombinant human endostatin and chemotherapy as the first-line treatment of advanced non-small-cell lung cancer.
Fu S; Huang H; Shang K; Tu G; Zhong P; Li S; Zhu X; Peng S; Liu Y; Lu Z; Chen L
Future Oncol; 2023 Jan; 19(2):147-158. PubMed ID: 36779488
[TBL] [Abstract][Full Text] [Related]
13. Molecular correlation of response to pyrotinib in advanced NSCLC with HER2 mutation: biomarker analysis from two phase II trials.
Mao S; Yang S; Liu X; Li X; Wang Q; Zhang Y; Chen J; Wang Y; Gao G; Wu F; Jiang T; Zhang J; Yang Y; Lin X; Zhu X; Zhou C; Ren S
Exp Hematol Oncol; 2023 Jun; 12(1):53. PubMed ID: 37296463
[TBL] [Abstract][Full Text] [Related]
14. Soluble biomarkers to predict clinical outcomes in non-small cell lung cancer treated by immune checkpoints inhibitors.
Ancel J; Dormoy V; Raby BN; Dalstein V; Durlach A; Dewolf M; Gilles C; Polette M; Deslée G
Front Immunol; 2023; 14():1171649. PubMed ID: 37283751
[TBL] [Abstract][Full Text] [Related]
15. Role of Neoadjuvant Immune Checkpoint Inhibitors in Resectable Non-Small Cell Lung Cancer.
Riano I; Abuali I; Sharma A; Durant J; Dragnev KH
Pharmaceuticals (Basel); 2023 Feb; 16(2):. PubMed ID: 37259381
[TBL] [Abstract][Full Text] [Related]
16. Neutrophil extracellular traps in tumor progression and immunotherapy.
Yan M; Gu Y; Sun H; Ge Q
Front Immunol; 2023; 14():1135086. PubMed ID: 36993957
[TBL] [Abstract][Full Text] [Related]
17. G-CSF Is a Novel Mediator of T-Cell Suppression and an Immunotherapeutic Target for Women with Colon Cancer.
Ray AL; Saunders AS; Nofchissey RA; Reidy MA; Kamal M; Lerner MR; Fung KM; Lang ML; Hanson JA; Guo S; Urdaneta-Perez MG; Lewis SE; Cloyde M; Morris KT
Clin Cancer Res; 2023 Jun; 29(11):2158-2169. PubMed ID: 36951682
[TBL] [Abstract][Full Text] [Related]
18. The efficacy and safety of continuous intravenous infusion of rh-endostatin combined with platinum-based doublet chemotherapy for advanced non-small-cell lung cancer.
Liu X; Guo Z; Su L; Zuo A; Gao M; Ji X; Lu J; Yang S; Jiang Y; Lu D
Invest New Drugs; 2024 May; ():. PubMed ID: 38700579
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
